IMADEK Snaps ￥10 Million in Series A Financing

(VCBeat) May. 7, 2021 -- Recently, Changsha Maidike Intelligent Technology Co., Ltd. ("IMADEK"), which focuses on the R&D of automated medical testing products, announces today that it has secured tens of millions of yuan in Series A financing from Lingxian Healthcare Fund owned by Yushan Capital. Funds raised in the latest round will be used to further expand production capacity and accelerate product development and upgrading.

IMADEK was founded in 2016, has been committed to the automated product development of blood tests and in vitro diagnostics. It is one of the few domestic suppliers that have fully independent intellectual property rights of automatic pipetting platform and automatic testing line. IMADEK aims to break the monopoly of imported brands through its own technologies in automated in vitro diagnosis and blood tests.

Wang Peng, the founder of IMADEK, has focused on the field of blood testing for 23 years. The company has independently developed products including the automated nucleic acid extraction workstation, cup processing system, automated sample processing system, intelligent blood supply platform and smart cold chain monitoring system, etc., all of which have been commercially available now.

After the launch of IMADEK's products, the company has received great attention. IMADEK has reached strategic cooperation with a number of domestic top enterprises of nucleic acid tests. The products are installed and applied in the domestic and foreign markets and gained a great reputation.

Lingxian Healthcare Fund is a venture capital fund founded by senior healthcare investment professionals dedicated to early-stage investments in the healthcare industry. Adhering to the concept of "dedicated, professional", the company deeply explores the development trend and investment opportunities of the medical and health industry, removes noises and distractions from the outside and pursues real investment returns.